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Abstract
Background: Recent genome wide association (GWA) studies identified two Single Nucleotide
Polymorphisms (SNP) (rs10757278 and rs10757274) in the region of the CDK2NA and CDK2NB
genes to be consistently associated with the risks of coronary heart disease (CHD) and myocardial
infarction (MI). We examined the SNPs in relation to the risk of CHD and MI in a large population
based study of elderly population.
Methods: The Rotterdam Study is a population-based, prospective cohort study among 7983
participants aged 55 years and older. Associations of the polymorphisms with CHD and MI were
assessed by use of Cox proportional hazards analyses.
Results: In an additive model, the age and sex adjusted hazard ratios (HRs) (95% confidence
interval) for CHD and MI were 1.03 (0.90, 1.18) and 0.94 (0.82, 1.08) per copy of the G allele of
rs10757274. The corresponding HRs were 1.03 (0.90, 1.18) and 0.93 (0.81, 1.06) for the G allele
of rs10757278. The association of the SNPs with CHD and MI was not significant in any of the
subgroups of CHD risk factors.
Conclusion: we were not able to show an association of the studied SNPs with risks of CHD and
MI. This may be due to differences in genes involved in the occurrence of CHD in young and older
people.
Background
It has been considered for long that genes play a substan-
tial role in susceptibility to coronary heart disease (CHD)
[1]. Up to now, a limited number of these genes have been
identified through the candidate gene approach and
genome wide linkage studies. Recently a number of
genome wide association (GWA) studies have identified
several genetic variants on chromosome 9p21 associated
with the risk of CHD. McPherson et al. found a Single
Nucleotide Polymorphism (SNP), rs10757274, on chro-
mosome 9p21 associated with the risk of CHD [2]. Helga-
dottir et al. found a close-by SNP, rs10757278, in the
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same 9p21 region associated with the risk of myocardial
infarction (MI) [3]. These findings were followed by
another GWA study by Samani et al [4], which found
rs1333049 to be associated with the risk of coronary artery
disease [4]. All three SNPs are located within the same
Linkage Disequilibrium (LD) block on chromosome 9
approximately 22 million base pairs from the 9p tel-
omere, adjacent to two tumor suppressor genes, CDKN2A
and CDKN2B. These genes are involved in regulation of
cell proliferation. Abnormal proliferation is one of the
characteristics of atherosclerosis, one of the pathological
features of CHD and MI [5].
To date, the findings are replicated in several case-control
studies comprising 12285 cases and 23184 controls and
two cohort studies comprising 22056 subjects [6-10].
These replications has made this locus one of the best rep-
licated findings for genetic susceptibility to cardiovascular
diseases. Though this findings are promising, they will be
of more clinical worth if translated to older patients who
constitute a larger part of the patients. We chose to study
rs10757278 and rs10757274 because they were most
strongly and consistently associated with CHD and MI in
GWA studies. The leading SNP of the study by Samani et
al, rs1333049, is in the same LD block with rs10757278
and contributes to the same haplotype alleles. We
attempted to replicate the association in the Rotterdam
Study, a population-based cohort study among older sub-
jects, but found no association.
Methods
Study Population
The study was conducted within the framework of the
Rotterdam Study, an ongoing prospective, population-
based cohort study on determinants of a number of
chronic diseases. The Rotterdam Study has been described
in detail elsewhere [11]. In brief, all inhabitants of
Ommoord, a district of Rotterdam in the Netherlands,
who were 55 years or over, were invited to participate in
this study. Of all 10275 eligible individuals, 7983 agreed
to participate (78%). Written informed consent was
obtained from all participants and the Medical Ethics
Committee of the Erasmus Medical Center approved the
study.
Baseline measurements
The baseline examinations took place from 1990–1993.
Participants were visited at home for an interview. Infor-
mation on current health status, medical history, use of
medication, and smoking status were obtained during the
interview. The interview was followed by two visits at the
research center for blood sampling and further examina-
tions.
At baseline, participants were asked whether they have
ever experienced a heart attack. A 12-lead electrocardio-
gram (ECG) was stored digitally and analyzed by using
the Modular ECG Analysis System (MEANS). Myocardial
infarction found on ECG was based on criteria partly
derived from the Minnesota code. A history of myocardial
infarction was considered present in case of a self-report
of myocardial infarction confirmed by ECG or additional
clinical information, or the presence of an ECG character-
istic of prior myocardial infarction [12,13].
Genotyping
Genomic DNA was extracted from leucocytes following
standard procedures. Participants were genotyped for
rs10757274 and rs10757278. Genotypes were deter-
mined in our study population in 2-ng genomic DNA by
use of pre-designed TaqMan SNP genotyping assay (Assay
ID C__26505812_10 and C__11841860_10, respectively;
Applied Biosystems, Foster City, CA). Reactions were per-
formed with the Taqman Prism 7900 HT 384 wells for-
mat.
Follow up
Follow up for clinical events started at baseline and follow
up examinations were carried out periodically in 1995–
1996, 1997–1999, and 2002–2004. Participants were
continuously monitored for fatal and nonfatal cardiovas-
cular events through automated linkage with files from
general practitioners and pharmacies working in the study
district of Ommoord. In addition, all medical records of
the participants under the care of general practitioners
outside the study area were checked annually. Two
research physicians independently coded all reported
events according to the International Classification of Dis-
eases, 10th edition (ICD-10). Codes on which the
research physicians disagreed were discussed to reach con-
sensus. Finally, a medical expert in cardiovascular disease,
whose judgment was considered final, reviewed all events.
Information on vital status was obtained regularly from
municipal health authorities in Rotterdam. For the
present study, follow up data were available until October
1, 2005.
Incident coronary heart disease and myocardial infarction
To identifying incident myocardial infarction and coro-
nary heart disease, we collected information from base-
line (1990 – 1993) until January 1, 2005. Fatal or non-
fatal MI reported by general practitioners in the research
area, letters from medical specialists and discharge reports
for hospitalized patients were the sources of information
used. Two research physicians coded the events independ-
ently and in case of disagreement the consensus was made
ina separate session. Finally a specialist whose judgment
was considered final verified the coding. We defined inci-
dent MI as fatal or non fatal MI (ICD-10 code I21). Inci-BMC Medicine 2008, 6:30 http://www.biomedcentral.com/1741-7015/6/30
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dent CHD was defined as fatal or nonfatal myocardial
infarction (ICD-10 code I21), coronary artery bypass
grafting (CABG), and percutaneous transluminal coro-
nary angioplasty (PTCA).
Population for analysis
The SNPs, rs10757274 and rs10757278 were genotyped
in 6251 and 6265 out of 7129 participants who visited the
research center at baseline.
Statistical analysis
Genotype frequencies were tested for Hardy-Weinberg
equilibrium with a chi-square test using The Hardy-Wein-
berg package for R http://www.r-project.org. To compare
the baseline characteristics between healthy subjects and
those who experienced CHD or MI, we used chi-square for
categorical variables and ANOVA for continuous varia-
bles.
A Cox regression analysis was used to assess the associa-
tion of SNPs with incident CHD and MI. The proportional
hazards assumption was validated by the use of a time-
dependent variable to check increasing or decreasing
trends in the hazard ratio (HR) over time. The basic model
was adjusted for age and sex. The multivariate adjusted
model was additionally adjusted for BMI, systolic and
diastolic blood pressure, total cholesterol, HDL choles-
terol, smoking, and diabetes.
To examine whether the effect of SNPs vary by the level of
other risk factors we performed the analysis stratified by
age, sex, family history of cardiovascular disease, HDL
cholesterol, diabetes, hypertension, smoking, and history
of CHD. For smoking, participants were categorized to
never, former, and current smokers. For hypertension and
diabetes, participants were categorized into those with
and without the condition. History of CHD was defined
as a history of MI, percutaneous transluminal coronary
angioplasty (PTCA) or coronary artery bypass grafting
(CABG). For other risk factors, the population was
divided into two equal subgroups by use of the median.
All statistical analyses were performed with the use of SAS,
version 8.
Results
Table 1 shows the baseline characteristics of the studied
population. CHD and MI cases were significantly older,
and more often male, hypertensive, diabetic, and smoker
than subjects without these conditions. Moreover, systolic
blood pressure, and total cholesterol were significantly
higher and HDL cholesterol was significantly lower in
CHD and MI cases. We found none of these characteristics
to be significantly associated with the studied SNPs.
During follow-up, 588 participants developed CHD, of
which 412 had experienced an MI. The mean follow-up
time was 9.5 years for CHD (incidence rate 9.9 per 1000
person years) and 9.5 years for MI (incidence rate 6.9 per
1000 person years). Mean (standard deviation) age of
onset was 68.6 (7.4) for CHD and 70.3 (7.8) years for MI.
We examined the associations of rs10757274 and
rs10757278 with risks of CHD and MI (table 2, 3 and 4).
None of the SNPs were significantly associated with the
risk of CHD or MI. The age and sex adjusted HR (95%
confidence interval [CI]) for CHD and MI were 1.03
(0.90, 1.18) and 0.94 (0.82, 1.08) per copy of G allele of
rs10757274, respectively. The corresponding HRs were
1.03 (0.90, 1.18) and 0.93 (0.81, 1.06) per copy of G
allele of rs10757278.
We repeated the analysis with incident cases limited to
those occurred before age 70. Age and sex adjusted HR
(95% CI) for CHD and MI were 1.00 (0.97, 1.04) and
0.90 (0.74, 1.09) per copy of G allele of rs10757274. The
corresponding HRs for MI were 1.00 (0.96, 1.04), and
0.91 (0.75, 1.10) per copy of G allele of rs10757278.
Table 1: Baseline characteristics of all participants, and of cases with incident MI and incident CHD
Characteristics All participants MI cases P value CHD cases P value
Number 6251 412 - 588 -
Age, mean (SD), y 69.5 (9.1) 70.3 (7.8) 0.02 68.6 (7.4) 0.23
Men, (%) 40.4 58.7 <0.001 61.2 <0.001
Body mass index, mean (SD), kg/m2 26.3 (3.7) 26.3 (3.5) 0.29 26.3 (3.4) 0.07
Waist circumference, mean (SD), cm 90.5 (11.2) 91.9 (10.0) 0.89 92.2 (10.2) 0.33
Systolic blood pressure, mean (SD), mm Hg 139.3 (22.2) 142.3 (21.9) 0.01 141.3 (21.7) 0.004
Diastolic blood pressure, mean (SD), mm Hg 73.7 (11.5) 73.7 (11.5) 0.77 73.7 (11.3) 0.38
Hypertension, (%) 34.3 40.6 0.006 40.2 0.002
Diabetes, (%) 10.5 17.0 <0.001 15.8 <0.001
Total cholesterol, mean (SD), mmol/L 6.6 (1.2) 6.9 (1.2) <0.001 6.9 (1.2) <0.001
HDL cholesterol, mean (SD), mmol/L 1.3 (0.4) 1.2 (0.3) <0.001 1.2 (0.3) <0.001
Current smoker, (%) 22.8 26.0 <0.001 27.1 <0.001
Former smoker, (%) 41.5 49.5 51.5BMC Medicine 2008, 6:30 http://www.biomedcentral.com/1741-7015/6/30
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To investigate whether any of the covariates affect the rela-
tion of SNPs with CHD and MI, we repeated the analysis
in subgroups of age, sex, family history of cardiovascular
disease, HDL cholesterol, diabetes, hypertension, smok-
ing, and history of CHD (figure 1). The association was
not significant in any of the studied subgroups and no sig-
nificant interaction was found.
Discussion
Our main goal was to replicate the results of recent GWA
studies on CHD and MI in a population based study. Two
SNPs, rs10757274 and rs10757278, which were most
consistently and strongly associated with the risk of CHD
in GWA studies were studied. We not only found no sig-
nificant association between these two SNPs and the risks
of CHD and MI, but also found, however non-significant,
an inverse direction for the risk. We also did not find an
association in subgroups of cardiovascular risk factors.
Different approaches have been used in recent decades to
discover causal genes for cardiovascular diseases. A novel
approach is the GWA study which searches large part of
the genome for predisposing variants. Contrary to the for-
merly common approach, the candidate gene study, the
GWA study is a hypothesis free approach, i.e. it holds no
prior assumption on the location of predisposing genes.
As an advantage, this approach promises a more compre-
hensive understanding of the causal genes. However, this
method is liable to false positive findings. Hence, GWA
studies always need to be replicated in independent sam-
ples to confirm their findings.
Our study had sufficient power to detect effect sizes as
shown in the published studies. In an additive model and
for a SNP with a minor allele frequency of 0.45 (lowest
minor allele frequency: 0.43, shown in Icelandic popula-
tion A [3]), our study had more than 80% power to detect
a relative risk of 1.15 for CHD (the lowest effect: 1.18,
shown in ARIC study [2]) and 1.23 for MI (the lowest
effect: 1.25, shown in the Iceland population A) [14].
We did not find any of the SNPs to be associated with the
risk of CHD in our study. One legitimate conjecture for
the inconsistency of our results with former studies may
be heterogeneity of the effect. Compared to the Rotterdam
Study, most of the studied populations comprised young
CHD or MI patients. If the risk allele on chromosome
9p21 invokes only early onset of CHD, the effect in older
subjects may not be large enough to be found in our
study. Therefore, our negative finding may point to a het-
erogeneity of effect by age. In agreement with this conjec-
ture, Helgadottir et al. showed that the association was
stronger when only those with early onset MI were consid-
ered [3]. However, we failed to find an evidence of age
affecting the association in our data. The strength of the
association did not change materially when we limited
the incident cases to those developed CHD or MI before
age 70. Moreover, the strength of the association was not
Table 2: The age and sex adjusted and multivariate adjusted association of the SNPs with incident CHD and MI
Allele All participants Incident cases Age and sex adjusted Multivariate adjusted HR*
CHD rs10757274 G 45.8 45.5 1.03 (0.90, 1.18) 1.00 (0.87, 1.15)
rs10757278 G 44.9 42.7 1.03 (0.90, 1.18) 1.00 (0.87, 1.15)
MI rs10757274 G 45.8 43.8 0.94 (0.82, 1.08) 0.97 (0.84, 1.11)
rs10757278 G 44.9 42.7 0.93 (0.81, 1.06) 0.95 (0.83, 1.10)
* adjusted for age, sex, BMI, serum total and HDL cholesterol, smoking, diabetes, systolic and diastolic blood pressure.
CI = Confidence interval, CHD = Coronary heart disease, MI = Myocardial infarction
Table 3: The age and sex adjusted and multivariate adjusted association of the SNPs with incident CHD
Participants (cases) Age and sex adjusted Multivariate adjusted *
rs10757274
AA 1834 (184) Reference Reference
AG 3107 (273) 0.89 (0.74, 1.07) 0.90 (0.74, 1.09)
GG 1310 (131) 1.00 (0.80, 1.26) 0.99 (0.78, 1.25)
rs10757278
AA 1909 (188) Reference Reference
AG 3097 (269) 0.90 (0.74, 1.08) 0.90 (0.74, 1.09)
GG 1264 (127) 1.01 (0.81, 1.27) 1.00 (0.79, 1.26)
* adjusted for age, sex, BMI, serum total and HDL cholesterol, smoking, diabetes, systolic and diastolic blood pressure.
CI = Confidence interval, CHD = Coronary heart disease, MI = Myocardial infarctionBMC Medicine 2008, 6:30 http://www.biomedcentral.com/1741-7015/6/30
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Table 4: The age and sex adjusted and multivariate adjusted association of the SNPs with incident MI
Participants (cases) Age and sex adjusted Multivariate adjusted *
rs10757274
AA 1832 (133) Reference Reference
AG 3106 (197) 0.90 (0.72, 1.12) 0.94 (0.75, 1.19)
GG 1309 (82) 0.89 (0.67, 1.17) 0.94 (0.70, 1.25)
rs10757278
AA 1907 (139) Reference Reference
AG 3096 (187) 0.85 (0.68, 1.06) 0.89 (0.71, 1.12)
GG 1263 (80) 0.88 (0.67, 1.16) 0.92 (0.70, 1.23)
* adjusted for age, sex, BMI, serum total and HDL cholesterol, smoking, diabetes, systolic and diastolic blood pressure.
CI = Confidence interval, CHD = Coronary heart disease, MI = Myocardial infarction
Association of rs10757274 and rs10757278 with CHD and MI in subgroups of cardiovascular risk factors Figure 1
Association of rs10757274 and rs10757278 with CHD and MI in subgroups of cardiovascular risk factors. The 
solid squares centered are on the hazard ratio estimate and scaled proportional to the sample size. Horizontal bars show the 
95% confidence interval.BMC Medicine 2008, 6:30 http://www.biomedcentral.com/1741-7015/6/30
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significantly different in age subgroups (figure 1). We
emphasis that our study may be underpowered to detect
the effect of age on the association. It is noteworthy that
the heterogeneity of effect has a particular clinical and
public health impact. In Western countries the majority of
morbidity and mortality from CHD occurs in elderly peo-
ple. In the Netherlands, 74% of men and 91% women
who experience fatal MI are older than 65 years http://stat
line.cbs.nl/statweb/. The fact that CHD is less common in
younger population implies that these subjects are not a
good representative of the general population of CHD
patients. Therefore, caution should be taken in generaliz-
ing the results of the published studies to an elderly pop-
ulation.
One may also speculate that those carrying the risk allele
had developed CHD at early age and were excluded at the
baseline in our study. If this is true, the prevalence of risk
allele should be higher in those who had a history of CHD
at baseline i.e. prevalent cases of CHD. To examine this
issue, we studied the association of the SNPs with preva-
lent CHD cases but found no association (data not
shown). Moreover, the frequencies of the alleles in our
population were high and comparable to former studies
making selection bias unlikely.
Previous studies mainly employed standard case-control
association studies. Our study has the advantage of
employing a different approach, the prospective study in
a large population based sample. One potential limitation
of our study is that the participants were not fully fol-
lowed and healthy subjects who carry the risk allele may
later develop the disease.
Conclusion
In conclusion, we showed that the studied SNPs are not
major players in development of CHD in the elderly pop-
ulation. Our negative finding offer a new perspective on
9p21 SNPs and shows that the association does not hold
for all CHD cases. The lack of association may be due to
the difference in genes involved in the development of
CHD in young and older people. Individualized preven-
tive measures and therapies constitute a major long-term
goal of GWA studies. Heterogeneity of the effect, there-
fore, has substantial public health impact and needs to be
acknowledged.
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